TAME Cardiac Arrest

ANZICS CTG Endorsed Study

TAME Cardiac Arrest

Targeted therapeutic mild hypercapnia after resuscitated cardiac arrest: A phase III multi-centre randomised controlled trial

Study Description

The TAME Cardiac Arrest trial will study the ability of higher carbon dioxide (CO2) levels to reduce brain damage, comparing giving patients ‘normal’ to ‘slightly higher than normal’ blood CO2 levels and assessing their ability to return to normal life-tasks. It will be the largest trial ever conducted in heart attack patients in the ICU. This therapy is cost free and, if shown to be effective, will improve thousands of Australian lives, transform clinical practice, and yield major savings.

Management Committee

Glenn Eastwood (Chair), John Archer, Rinaldo Bellomo, Stephen Bernard, Carol Hodgson, Shay McGuinness, Alistair Nichol, Niklas Nielsen, Rachael Parke, Markus Skrifvars, Dion Stub, and Fabio Taccone.

Project Manager

Bridget Ady (TAME Project Manager, ANZIC RC)
Kate Ainscough (TAME Project Manager, ICCTN, Ireland)

Administering Institution

ANZIC-Research Centre, Monash University


Irish Critical Care – Clinical Trials Group

Sample Size

1700 patients


National Health & Medical Research Council
Irish Health Research Board

Project Status as of June 2018

Recruitment has now commenced into the TAME trial.  There are currently 3 vanguard sites screening and enrolling participants.  The case report form and electronic database should be finalised by the end of June 2018.  The randomisation module is currently active.  Ethics approval has been completed in 11/18 regions and trial coordination is being led by Ms Bridget Ady (TAME project manager, ANZIC RC) in conjunction with Dr Kate Ainscough (TAME project manager, ICCTN, Ireland).  Major site start-ups are planned for July, 2018-October 2018 for local Australian sites as well as those of our international collaborators.


Glenn Eastwood (email)


ANZCTR: ACTRN12617000036314p